Reneo Pharmaceuticals, Inc. RPHM
18.20 +18.20
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 2.25 -87.6% downside
Now 18.20
- Target (low)
- 1.50
- Target (mean)
- 2.25
- Target (high)
- 3.00
Ratings (-1m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.07 | -0.07 – -0.07 | -0.57 | +87.7% | 0 | 0.0% | 1 |
| Next quarter | -0.07 | -0.07 – -0.07 | -0.71 | +90.1% | 0 | 0.0% | 1 |
| Current year | -0.65 | -0.65 – -0.65 | -2.52 | +74.2% | 0 | 0.0% | 1 |
| Next year | 0.00 | 0.00 – 0.00 | -0.65 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 11, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 27, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Jul 2, 2023 | B of A Securities | Initiated | — | Buy |
| May 17, 2022 | Piper Sandler | Maintained | — | Overweight |
| Mar 23, 2022 | SVB Leerink | Maintained | — | Outperform |
| Jan 26, 2022 | Baird | Initiated | — | Outperform |
| Dec 20, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 21, 2021 | Ladenburg Thalmann | Initiated | — | Buy |
| May 3, 2021 | Piper Sandler | Initiated | — | Overweight |
| May 3, 2021 | Jefferies | Initiated | — | Buy |
| May 3, 2021 | SVB Leerink | Initiated | — | Outperform |